Eli Lilly's shares reached all-time highs following the presentation of new data on retatrutide, a next-generation obesity drug, at the American Diabetes Association conference. This drug demonstrated a 19% weight loss at a lower 4-milligram dose, comparable to the maximum dose of Lilly's existing obesity treatment, Zepbound.
Analysts from Goldman Sachs and Barclays expressed optimism about Lilly's expanding obesity pipeline, highlighting retatrutide's potential for strong efficacy and tolerability. The company is seen as gaining a competitive edge in the obesity market, especially as its stock has risen 35% from year-to-date lows and 85% from its 52-week low.
Jim Cramer noted that while the stock has experienced a parabolic rise, he believes in holding onto it due to the strength of Lilly's drug pipeline and the broader health benefits of GLP-1 drugs. He criticized employers and insurers for limiting coverage of these therapies, arguing that their long-term health benefits justify the costs.
Overall, the developments suggest a robust future for Eli Lilly in the obesity treatment sector and beyond